0

Close
 
Upcoming Allied Market Research
2023
Retinoic Acid Market

Retinoic Acid Market

by Mode of Administration (Oral, External) and by End User (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A03706
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Retinoic Acid Market

Request Now !

Retinoic acid is a metabolite of vitamin A (retinol) that mediates the functions of vitamin A required for growth and development. It is a member of family of retinoids, that are compound either derived from vitamin A or are structurally similar to it.

Rise in incidences of cancers as retinoids find an important application in cancer therapeutics drive the market. In addition, retinoic acid is widely used for the treatment of photoaged skin, psoriasis, skin lesions of Kaposis sarcoma, and for cancers of breast and prostate also fuel the market growth. However, isotretinoin; a form of retinoic acid; is highly teratogenic.

As teratogenic drug can disturb the development of an embryo, therefore the use of retinoic acid is strictly controlled. This restrains the market growth. Conversely, increase in research for the cure of cancers and advancements in cancer therapeutics provide ample opportunities for the market growth.

The retinoic acid market is segmented on the basis of mode of administration, end user, and region. Based on mode of administration, the market is categorized into oral retinoids and external retinoids. By end user, it is classified into hospital pharmacy, retail pharmacy, and online pharmacy. By geography, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players operating in the market include LGM Pharma, GF Health Products, Inc., GYMA Laboratories of America, Inc., Genemed Synthesis Inc., IMCoPharma a. s., Chongqing Huabang Pharmacy Co., Ltd., Olon S.p.A., and Sun Pharmaceutical Industries Ltd.

Key Benefits

  • The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • Key players are profiled and their strategies are analyzed thoroughly, which explains the competitive outlook of the global market.
  • The report offers a quantitative analysis to enable the stakeholders to capitalize on the prevailing market opportunities.

 Retinoic Acid Market Report Highlights

Aspects Details
By Mode of Administration
  • Oral
  • External
By End User
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Genemed Synthesis Inc., The Derma Company, Olon S.p.A., GYMA Laboratories of America, Inc., Sun Pharmaceutical Industries Ltd., IMCoPharma a. s., GF Health Products, Inc., Mama Earth, LGM Pharma, Chongqing Huabang Pharmacy Co., Ltd.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: RETINOIC ACID MARKET, BY MODE OF ADMINISTRATION

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Mode Of Administration

    • 4.2. Oral

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. External

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: RETINOIC ACID MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospital Pharmacy

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Online Pharmacy

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Retail Pharmacy

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: RETINOIC ACID MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Mode Of Administration

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Retinoic Acid Market

        • 6.2.5.1. Market Size and Forecast, By Mode Of Administration
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Retinoic Acid Market

        • 6.2.6.1. Market Size and Forecast, By Mode Of Administration
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Retinoic Acid Market

        • 6.2.7.1. Market Size and Forecast, By Mode Of Administration
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Mode Of Administration

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Retinoic Acid Market

        • 6.3.5.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Retinoic Acid Market

        • 6.3.6.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Retinoic Acid Market

        • 6.3.7.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Retinoic Acid Market

        • 6.3.8.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Retinoic Acid Market

        • 6.3.9.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Retinoic Acid Market

        • 6.3.10.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Retinoic Acid Market

        • 6.3.11.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Mode Of Administration

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Retinoic Acid Market

        • 6.4.5.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Retinoic Acid Market

        • 6.4.6.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Retinoic Acid Market

        • 6.4.7.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Retinoic Acid Market

        • 6.4.8.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Retinoic Acid Market

        • 6.4.9.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Retinoic Acid Market

        • 6.4.10.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Retinoic Acid Market

        • 6.4.11.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Retinoic Acid Market

        • 6.4.12.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Retinoic Acid Market

        • 6.4.13.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Mode Of Administration

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Retinoic Acid Market

        • 6.5.5.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Retinoic Acid Market

        • 6.5.6.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Retinoic Acid Market

        • 6.5.7.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Retinoic Acid Market

        • 6.5.8.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Retinoic Acid Market

        • 6.5.9.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Retinoic Acid Market

        • 6.5.10.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. LGM Pharma

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. GF Health Products, Inc.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. GYMA Laboratories Of America, Inc.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Genemed Synthesis Inc.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. IMCoPharma A. S.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Chongqing Huabang Pharmacy Co., Ltd.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Olon S.p.A.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Sun Pharmaceutical Industries Ltd.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Mama Earth

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. The Derma Company

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL RETINOIC ACID MARKET, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL RETINOIC ACID MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL RETINOIC ACID MARKET FOR EXTERNAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL RETINOIC ACID MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL RETINOIC ACID MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL RETINOIC ACID MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL RETINOIC ACID MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL RETINOIC ACID MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. NORTH AMERICA RETINOIC ACID, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 12. U.S. RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 13. U.S. RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 14. CANADA RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 15. CANADA RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. MEXICO RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 17. MEXICO RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 18. EUROPE RETINOIC ACID, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. FRANCE RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 22. FRANCE RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 25. ITALY RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 26. ITALY RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. SPAIN RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 28. SPAIN RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. UK RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 30. UK RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. RUSSIA RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 32. RUSSIA RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC RETINOIC ACID, BY REGION, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 38. CHINA RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 39. CHINA RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. JAPAN RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 41. JAPAN RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. INDIA RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 43. INDIA RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 44. SOUTH KOREA RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 45. SOUTH KOREA RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. AUSTRALIA RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 47. AUSTRALIA RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. THAILAND RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 49. THAILAND RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. MALAYSIA RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 51. MALAYSIA RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. INDONESIA RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 53. INDONESIA RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. LAMEA RETINOIC ACID, BY REGION, 2022-2032 ($MILLION)
  • TABLE 57. LAMEA RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 58. LAMEA RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. BRAZIL RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 60. BRAZIL RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. SOUTH AFRICA RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 62. SOUTH AFRICA RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 63. SAUDI ARABIA RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. SAUDI ARABIA RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. UAE RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 66. UAE RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. ARGENTINA RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 68. ARGENTINA RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 69. REST OF LAMEA RETINOIC ACID, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF LAMEA RETINOIC ACID, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. LGM PHARMA: KEY EXECUTIVES
  • TABLE 72. LGM PHARMA: COMPANY SNAPSHOT
  • TABLE 73. LGM PHARMA: OPERATING SEGMENTS
  • TABLE 74. LGM PHARMA: PRODUCT PORTFOLIO
  • TABLE 75. LGM PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 76. GF HEALTH PRODUCTS, INC.: KEY EXECUTIVES
  • TABLE 77. GF HEALTH PRODUCTS, INC.: COMPANY SNAPSHOT
  • TABLE 78. GF HEALTH PRODUCTS, INC.: OPERATING SEGMENTS
  • TABLE 79. GF HEALTH PRODUCTS, INC.: PRODUCT PORTFOLIO
  • TABLE 80. GF HEALTH PRODUCTS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. GYMA LABORATORIES OF AMERICA, INC.: KEY EXECUTIVES
  • TABLE 82. GYMA LABORATORIES OF AMERICA, INC.: COMPANY SNAPSHOT
  • TABLE 83. GYMA LABORATORIES OF AMERICA, INC.: OPERATING SEGMENTS
  • TABLE 84. GYMA LABORATORIES OF AMERICA, INC.: PRODUCT PORTFOLIO
  • TABLE 85. GYMA LABORATORIES OF AMERICA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. GENEMED SYNTHESIS INC.: KEY EXECUTIVES
  • TABLE 87. GENEMED SYNTHESIS INC.: COMPANY SNAPSHOT
  • TABLE 88. GENEMED SYNTHESIS INC.: OPERATING SEGMENTS
  • TABLE 89. GENEMED SYNTHESIS INC.: PRODUCT PORTFOLIO
  • TABLE 90. GENEMED SYNTHESIS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. IMCOPHARMA A. S.: KEY EXECUTIVES
  • TABLE 92. IMCOPHARMA A. S.: COMPANY SNAPSHOT
  • TABLE 93. IMCOPHARMA A. S.: OPERATING SEGMENTS
  • TABLE 94. IMCOPHARMA A. S.: PRODUCT PORTFOLIO
  • TABLE 95. IMCOPHARMA A. S.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. CHONGQING HUABANG PHARMACY CO., LTD.: KEY EXECUTIVES
  • TABLE 97. CHONGQING HUABANG PHARMACY CO., LTD.: COMPANY SNAPSHOT
  • TABLE 98. CHONGQING HUABANG PHARMACY CO., LTD.: OPERATING SEGMENTS
  • TABLE 99. CHONGQING HUABANG PHARMACY CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 100. CHONGQING HUABANG PHARMACY CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. OLON S.P.A.: KEY EXECUTIVES
  • TABLE 102. OLON S.P.A.: COMPANY SNAPSHOT
  • TABLE 103. OLON S.P.A.: OPERATING SEGMENTS
  • TABLE 104. OLON S.P.A.: PRODUCT PORTFOLIO
  • TABLE 105. OLON S.P.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 107. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 108. SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 109. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 110. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. MAMA EARTH: KEY EXECUTIVES
  • TABLE 112. MAMA EARTH: COMPANY SNAPSHOT
  • TABLE 113. MAMA EARTH: OPERATING SEGMENTS
  • TABLE 114. MAMA EARTH: PRODUCT PORTFOLIO
  • TABLE 115. MAMA EARTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. THE DERMA COMPANY: KEY EXECUTIVES
  • TABLE 117. THE DERMA COMPANY: COMPANY SNAPSHOT
  • TABLE 118. THE DERMA COMPANY: OPERATING SEGMENTS
  • TABLE 119. THE DERMA COMPANY: PRODUCT PORTFOLIO
  • TABLE 120. THE DERMA COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL RETINOIC ACID MARKET SEGMENTATION
  • FIGURE 2. GLOBAL RETINOIC ACID MARKET
  • FIGURE 3. SEGMENTATION RETINOIC ACID MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN RETINOIC ACID MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALRETINOIC ACID MARKET
  • FIGURE 11. RETINOIC ACID MARKET SEGMENTATION, BY BY MODE OF ADMINISTRATION
  • FIGURE 12. RETINOIC ACID MARKET FOR ORAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. RETINOIC ACID MARKET FOR EXTERNAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. RETINOIC ACID MARKET SEGMENTATION, BY BY END USER
  • FIGURE 15. RETINOIC ACID MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. RETINOIC ACID MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. RETINOIC ACID MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 19. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 20. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 21. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 22. COMPETITIVE DASHBOARD
  • FIGURE 23. COMPETITIVE HEATMAP: RETINOIC ACID MARKET
  • FIGURE 24. Top player positioning, 2022
  • FIGURE 25. LGM PHARMA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 26. LGM PHARMA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 27. LGM PHARMA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 28. GF HEALTH PRODUCTS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 29. GF HEALTH PRODUCTS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 30. GF HEALTH PRODUCTS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 31. GYMA LABORATORIES OF AMERICA, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. GYMA LABORATORIES OF AMERICA, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. GYMA LABORATORIES OF AMERICA, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. GENEMED SYNTHESIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. GENEMED SYNTHESIS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. GENEMED SYNTHESIS INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. IMCOPHARMA A. S.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. IMCOPHARMA A. S.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. IMCOPHARMA A. S.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. CHONGQING HUABANG PHARMACY CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. CHONGQING HUABANG PHARMACY CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. CHONGQING HUABANG PHARMACY CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. OLON S.P.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. OLON S.P.A.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. OLON S.P.A.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. MAMA EARTH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. MAMA EARTH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. MAMA EARTH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. THE DERMA COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. THE DERMA COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. THE DERMA COMPANY: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Retinoic Acid Market

Start reading.
This Report and over 68,246+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers